Tetra Bio-Pharma Inc. (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced its first sale of its Rx Princeps inhalation device. The sale of this inhalation device is the first step towards the sale of Rx Princeps, a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a consistent composition of THC and CBD from lot-to-lot.
According to the company’s statement: "I am happy to announce the first batch order of our medical cannabis inhalation devices. This is the first step in generating a steady revenue stream and it is the beginning of a new phase in our development. Sales of Rx Princeps inhalation device will be an additional revenue stream for Tetra. Our inhalation device is a unique, high quality, CSA-approved customized titanium pipe, designed by our partner, Ford Pharmacy. With this launch, Tetra is providing a high quality, standardized treatment with clinical data to patients in need."
As Rx Princeps will soon be launched under ACMPR through Aphria, and the company is expecting to generate $1.5 millions in sales, in fiscal 2018.
“Through promotion and education efforts in Quebec, New Brunswick, and part of Ontario, Tetra Bio-Pharma estimates that over eight thousand patients will start using Rx Princeps under prescription from their doctors over in the next twelve months," states Bernard Fortier, CEO of Tetra.
Fortier highlights that "It is important to consider that only 4% of physicians today consider prescribing cannabis. A fixed-dose approach, as we are promoting based on our original clinical data, is attractive to doctors because the treatment dose is standardized. We have a huge opportunity in educating doctors on our clinical approach."
Tetra has received its first sales order from Sante Cannabis. Sante Cannabis is the first cannabinoid clinic and medical marijuana resource centre in Quebec.
Rx Princeps allows patients to optimize the benefits of medical cannabis through the intake of a standardized amount of product. The Rx Princeps inhalation device is an essential accessory to ensure consistency of treatment, as well as optimize the potency of the product, while minimizing wastes for the patient.
200,000 patients are already registered under Canada’s ACMPR program and around 1.5 million adults in Canada suffer from chronic pain and are considered non-responders to opioids; medical cannabis could be a therapeutic answer for those patients, but physicians need bioavailability and safety data to prescribe medical cannabis with confidence.
Rx Princeps is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in a Phase 1 clinical trial. Rx Princeps™ will be available across Canada, through Licensed Producer Aphria Inc., for patients who have a prescription from their physicians.
More information is available on their website.